Skeletal Preservation in Prostate Cancer: The Changing Role of the Urologist

European Urology, Supplements

Volumn 5, Issue 17, 2006, Pages 871-872

  Clarke, Noel W ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; ZOLEDRONIC ACID;

ANDROGEN DEPRIVATION THERAPY; ANDROGEN THERAPY; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE METASTASIS; EDITORIAL; HUMAN; MORBIDITY; OSTEOLYSIS; PATIENT CARE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RECURRENT DISEASE; TREATMENT DURATION; UROLOGY;

EID: 33748928980     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2006.06.019     Document Type: Editorial

References (3)

1. Smith M.R., Eastham J., Gleason D.M., Shasha D., Tchekmedyian S., and Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 169 (2003) 2008-2012
2. Saad F., Gleason D.M., Murray R., et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94 (2002) 1458-1468
3. Saad F., Gleason D.M., Murray R., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-882